VBI Vaccines launches of first ever 3-antigen hep B vaccine PreHevbrio in USA
VBI Vaccines (Nasdaq: VBIV) shares were up 10.4% at $1.75 by midday on Tuesday, after it announced commercial availability of PreHevbrio, the only Food and Drug Administration-approved 3-antigen hepatitis B virus vaccine for adults.
PreHevbrio is the only vaccine that mimics all three surface antigens of the hepatitis B virus, and was proven to provide adults with significantly higher seroprotection than a monovalent vaccine in a head-to-head Phase III clinical trial. l
The launch of PreHevbrio comes on the heels of the CDC Advisory Committee on Immunization Practices (ACIP) February 2022 meeting, when PreHevbrio was added to the list of recommended products for adult vaccination against HBV infection. PreHevbrio received FDA approval on November 30, 2021.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze